Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo

NEW YORK, November 10, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.

--
Actavis plc Research Reports
On November 5, 2014, Actavis plc (Actavis) announced its Q3 2014 financial results. Net revenues during the quarter increased 83.0% YoY to $3.7 billion. North America Brands segment net revenue were $1.6 billion in Q3 2014, compared to $153.0 million in Q3 2013. For the quarter, Actavis reported net loss of $1.0 billion, or $3.95 loss per diluted share, compared with net income of $65.6 million, or $0.49 loss per diluted share, in Q3 2013. On an adjusted basis, the Company's diluted EPS increased to $3.19 from $2.09 in Q3 2013. According to CEO and President, Brent Saunders, the growth in earnings was attributed to strong contributions from its new brand pharmaceutical portfolios, resulting from the acquisitions of Warner Chilcott and Forest, as well as strong growth in its U.S. Generics and International businesses and the Anda Distribution business. On average, analysts polled by Reuters expected Actavis to report Q3 2014 EPS at $3.10 on revenue of $3.63 billion. For full-year 2014, Actavis anticipates non-GAAP EPS to be between $13.51 to $13.61. The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Nov-10-2014/ACT/report.pdf

--
Celgene Corporation Research Reports
On October 31, 2014, Celgene Corporation (Celgene) released an update on its planned participations in the upcoming investor conferences and Medical Congress. On November 11, 2014, Celgene will present at the Credit Suisse Healthcare Conference in Phoenix at 3:00 p.m. ET; on December 2, 2014, it will present at the Deutsche Bank BioFEST Conference in Boston at 3:25 p.m. ET; and on December 7, 2014, Celgene will present at the American Society of Hematology (ASH) in San Francisco at 11:00 p.m. ET. Celgene informed that the live webcast of these conferences and event will be available in the Investor Relations section of its website. The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Nov-10-2014/CELG/report.pdf

--
UnitedHealth Group Incorporated Research Reports
On November 5, 2014, UnitedHealth Group Inc. reported that its Company UnitedHealthcare has launched the AARP MedicareComplete Focus (HMO) Medicare Advantage plan, a new Medicare Advantage plan in the Jacksonville area that will feature a medical home model of care management to help people save money and improve their health and well-being. WellMed physicians will coordinate the care for beneficiaries who enroll in the new plan, the Company said. According to UnitedHealthcare, more than 169,000 Medicare beneficiaries in Clay and Duval counties can enroll in the plan during the Open Enrollment Period (October 15 - December 7, 2014). The Company informed that the plan has a $0 monthly premium beyond the Part B premium, and includes coverage of prescription drugs, a SilverSneakers fitness membership and UnitedHealthcare's Passport program. The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Nov-10-2014/UNH/report.pdf

--
Jazz Pharmaceuticals plc Research Reports
On November 4, 2014, Jazz Pharmaceuticals plc (Jazz) announced its Q3 2014 financial results. Total revenues increased 32.1% YoY to $306.6 million, driven primarily by net product sales of Xyrem oral solution, Erwinaze/Erwinase and Defitelio. Revenues beat the analysts' estimates of $302.48 million for the quarter, according to Reuters. Net income was reported at $25.8 million, or $0.41 per diluted share, compared to $75.4 million, or $1.23 per diluted share in Q3 2013. Jazz's Q3 2014 net income included an upfront payment of $75.0 million for the rights to defibrotide in the Americas. Adjusted diluted EPS stood at $2.33 per share, beating the average estimate of $2.22 per share in a Reuters' analysts poll. For full-year 2014, Jazz expects revenues in the range of $1,150 million-$1,170 million, and adjusted EPS in the range of $8.20-$8.35. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Nov-10-2014/JAZZ/report.pdf

--
Endo International plc Research Reports
On November 5, 2014, Endo International plc (Endo) announced its Q3 2014 financial results. Total revenues came in at $763.9 million, up 15.5% YoY, helped mainly by strong growth in U.S. Generic Pharmaceuticals sales which also offset the decline in U.S. Branded Pharmaceuticals sales. For the quarter, Endo reported net loss of $252.1 million, or $1.64 per diluted share, compared to net income of $40.2 million, or $0.33 per diluted share in Q3 2013. On an adjusted basis, Endo earned $1.15 per diluted share, versus $1.34 per diluted share in Q3 2013. Analysts polled by Reuters expected the Company to report adjusted EPS of $1.00 on revenues of $725.71 million. Endo has also revised its full-year 2014 guidance. While revenue guidance range has been lowered to $2.80 billion and $2.88 billion, the adjusted EPS range has been raised to $4.10 and $4.25. The full research reports on Endo are available to download free of charge at:

http://www.analystsreview.com/Nov-10-2014/ENDP/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review